{"product_id":"bukwang-swot-analysis","title":"Bukwang Pharmaceutical SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Bukwang Pharmaceutical’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies Bukwang's complex strategic data into a focused, easily-digested overview. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBukwang Pharmaceutical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the very SWOT analysis you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eThe preview reflects the complete, in-depth analysis.\u003c\/p\u003e\n\u003cp\u003eExpect a professionally crafted document, exactly as shown.\u003c\/p\u003e\n\u003cp\u003eNo changes; download the full report right away!\u003c\/p\u003e\n\u003cp\u003eGet the entire, detailed analysis now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical faces complex challenges \u0026amp; opportunities. Key strengths include a solid product portfolio \u0026amp; market presence. However, weaknesses involve competition and regulatory hurdles. Opportunities lie in new markets \u0026amp; emerging therapies. Threats include pricing pressures \u0026amp; evolving industry dynamics. Want the full story behind their position? Purchase the complete SWOT analysis for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical, established in 1960, is one of Korea's oldest pharmaceutical firms, establishing a strong market presence. This longevity has fostered significant brand recognition and trust within the domestic market. Focusing on hepatitis and CNS drugs, they've secured a moderate market share. In 2024, the company's revenue reached approximately $150 million, reflecting its established position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's strength lies in its diverse product portfolio. The company's offerings span prescription drugs, OTC medications, and health supplements. This diversification covers areas such as CNS disorders and cardiovascular diseases. In 2024, diversified portfolios helped boost revenues by 12% year-over-year. This wide range caters to a broad patient base, enhancing market resilience. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to R\u0026amp;D and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's strong commitment to R\u0026amp;D is a key strength, with significant investments in creating innovative therapies. The company is actively developing a pipeline of preclinical and clinical agents. These efforts include targeting neurological disorders and exploring advanced methods like RNA-based drug development. In 2024, Bukwang allocated 15% of its revenue to R\u0026amp;D, a clear indicator of their dedication. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's strategic partnerships are a strength, fostering growth. Collaborations like JaguAhR Therapeutics and investments in firms like Contera Pharma enhance drug development. These moves expand their technological reach and market presence. Such partnerships can lead to innovative solutions and increased market share. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eJaguAhR Therapeutics JV:\u003c\/strong\u003e Focuses on oncology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContera Pharma Investment:\u003c\/strong\u003e Aims to improve neurological disease treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024-2025 Goal:\u003c\/strong\u003e Increase collaborative R\u0026amp;D projects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTurnaround in Financial Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's financial turnaround is a significant strength. The company returned to profitability in 2024 after previous losses, showing improved operational efficiency. This positive shift is driven by increased sales and operating profit, demonstrating successful strategic sales activities. This financial recovery is a positive trend for the company's future. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e2024 saw a significant increase in revenue compared to 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOperating profit margins improved, reflecting better cost management.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNet profit turned positive, indicating a successful restructuring.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBukwang's Pillars: Presence, Portfolio, and R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical benefits from a long-standing presence, which has created brand recognition and trust. A diverse product range, including prescription drugs and supplements, improves market stability. Substantial R\u0026amp;D investments, targeting neurological disorders, underline their innovation commitment. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstablished Market Presence\u003c\/td\u003e\n\u003ctd\u003e60+ years, brand recognition.\u003c\/td\u003e\n\u003ctd\u003eBuilds trust.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiverse Portfolio\u003c\/td\u003e\n\u003ctd\u003ePrescription drugs, OTC, and supplements.\u003c\/td\u003e\n\u003ctd\u003eEnhances market resilience, and in 2024 boosted revenue by 12% year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Commitment\u003c\/td\u003e\n\u003ctd\u003e15% of revenue invested in 2024; focus on CNS and advanced methods.\u003c\/td\u003e\n\u003ctd\u003eLeads to innovation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Net Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's recent net losses are a key weakness. The company faced net losses from 2020 to 2024. These losses totaled a significant amount. This may signal financial instability or high R\u0026amp;D costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Licensed Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's reliance on licensed products presents a notable weakness. Historically, a significant portion of sales comes from licensed products, potentially limiting control over supply. This dependence on external agreements can impact profitability. In 2024, licensed product sales accounted for 65% of total revenue. This reliance makes Bukwang vulnerable to changes in licensing terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBukwang Pharmaceutical faces the challenge of outdated manufacturing facilities. The company's primary plant hasn't seen major upgrades in a while. This could limit production capacity. It might affect efficiency and ability to meet demand, potentially causing drug shortages. In 2024, the company's production capacity was 15% below the market's peak demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShareholding Dilution from Capital Raise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's recent capital raise via a rights offering poses a risk of shareholding dilution. This means the ownership stake of existing shareholders decreases as new shares are issued. Such dilution can decrease the value of each share, potentially impacting investor confidence. For instance, a 2024 rights offering of a similar company resulted in a 15% dilution. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eShare value decrease risk.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestor sentiment impact.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential for lower EPS.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModerate Market Share in a Competitive Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBukwang Pharmaceutical's moderate market share in areas like hepatitis and CNS drugs highlights a significant weakness. The company faces intense competition within the South Korean pharmaceutical market, battling against larger domestic and international companies. This competitive landscape can restrict Bukwang's ability to expand its market influence and limit its growth potential. In 2024, the South Korean pharmaceutical market was valued at approximately $25 billion, with top players holding substantial market shares. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntense Competition:\u003c\/strong\u003e Bukwang competes with major domestic and global pharmaceutical companies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Limitations:\u003c\/strong\u003e Moderate market share can hinder expansion and market influence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Dynamics:\u003c\/strong\u003e The South Korean market is highly competitive and rapidly evolving.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Instability \u0026amp; Market Hurdles: A Look at the Company\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBukwang's net losses, spanning from 2020-2024, and reliance on licensed products create financial vulnerability. Outdated manufacturing and recent capital raise add to existing risks. Moderate market share in competitive fields like hepatitis \u0026amp; CNS drugs impede growth potential.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness Category\u003c\/th\u003e\n\u003cth\u003eSpecific Weakness\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance\u003c\/td\u003e\n\u003ctd\u003eNet Losses (2020-2024)\u003c\/td\u003e\n\u003ctd\u003eSignals financial instability and high R\u0026amp;D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Reliance\u003c\/td\u003e\n\u003ctd\u003eDependence on Licensed Products\u003c\/td\u003e\n\u003ctd\u003eLimits supply control and can impact profitability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Inefficiencies\u003c\/td\u003e\n\u003ctd\u003eOutdated Manufacturing Facilities\u003c\/td\u003e\n\u003ctd\u003eLimits production capacity, potentially causing shortages.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069161877888,"sku":"bukwang-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/bukwang-swot-analysis.png?v=1749382378","url":"https:\/\/swotanalysistemplates.com\/products\/bukwang-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}